Cutter & CO Brokerage Inc. Sells 7,129 Shares of Novo Nordisk A/S (NYSE:NVO)

Cutter & CO Brokerage Inc. trimmed its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 2.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 282,972 shares of the company's stock after selling 7,129 shares during the period. Novo Nordisk A/S comprises about 4.6% of Cutter & CO Brokerage Inc.'s portfolio, making the stock its 3rd largest holding. Cutter & CO Brokerage Inc.'s holdings in Novo Nordisk A/S were worth $19,650,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. GQG Partners LLC boosted its stake in Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after buying an additional 5,556,460 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after acquiring an additional 2,947,771 shares during the last quarter. Nuveen Asset Management LLC boosted its holdings in Novo Nordisk A/S by 73.2% in the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after purchasing an additional 2,639,693 shares during the last quarter. Two Sigma Investments LP acquired a new position in Novo Nordisk A/S in the 4th quarter valued at about $158,657,000. Finally, Clearbridge Investments LLC boosted its holdings in Novo Nordisk A/S by 59.8% in the 4th quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock valued at $368,451,000 after purchasing an additional 1,602,549 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 2.2%

Shares of NYSE NVO traded down $1.46 during mid-day trading on Thursday, hitting $65.58. The company had a trading volume of 3,858,524 shares, compared to its average volume of 7,349,915. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The company has a market capitalization of $292.83 billion, a PE ratio of 19.44, a price-to-earnings-growth ratio of 1.29 and a beta of 0.64. The business's 50-day simple moving average is $70.36 and its 200 day simple moving average is $74.67. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The business had revenue of $11.87 billion for the quarter. On average, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NVO. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. BMO Capital Markets reaffirmed a "market perform" rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.